Biotech Showcase™ Celebrates Record Attendance by Life Science Investors, CEOs

Sara Jane Demy, CEO, Demy-Colton, and Anna Chrisman, Group Managing Director, EBD Group

NEW YORK & SAN FRANCISCO & CARLSBAD, Calif.--(BUSINESS WIRE)--Biotech Showcase™, one of the most influential international biotechnology investor conferences in the world, concluded in San Francisco the second week of January and brought together more than 3,600 decision makers and biotech investors shaping the biopharmaceutical industry. This year’s event marks the largest number of investors and overall attendees in the eleven-year history of the conference. Biotech Showcase is produced jointly by Demy-Colton and EBD Group.

“During healthcare’s busiest week of the year, we are proud to be the leading platform for small- and mid-cap public and private biotech companies to explore investment opportunities that drive innovation and advance life-changing therapeutics,” said Sara Jane Demy, founder and CEO, Demy-Colton. “This year, we had more attendees than ever before, including a record number of investors meeting with companies and attending company presentations. This investor interest at both Biotech Showcase and Digital Medicine & Medtech Showcase is what has attracted the most exciting and cutting-edge companies year after year. Taken together, this speaks to the impressive growth and high value that this conference, and the surrounding week of activities, holds for the biotech industry.”

“Now in our eleventh year, we are pleased that Biotech Showcase continues to see record numbers of attendees with a strong showing from both public and private presenting companies and more than 1,000 registered investors,” said Anna Chrisman, Group Managing Director, EBD Group. “The announcements and discussions heard in the hallways, partnering rooms, and presentation stages throughout the conference provides key insights into the life science community and highlights the trends that will shape the industry in the coming year.”

Some of the world’s leading biotech and pharmaceutical investors joined CEOs, executives, and industry advisors in multiple panels, plenary sessions, and workshops covering a wide variety of timely trends and issues facing the industry. Reexamination of Alzheimer’s disease, discussions on the state of industry financing, exploration of the RNA therapeutic landscape, the outlook on gene therapy, and progress in rare and orphan diseases were just a few of the topics addressed this year.

“Biotech Showcase offers a unique opportunity for life science investors to gather and learn about new technologies and the progress of an amazing array of innovative companies. Each year, our face to face interactions with promising biotechnology companies provides significant value by helping to inform our investing decisions over the next few years,” said Eric Aguiar, MD, partner at Aisling Capital. “The programming and structure of the conference continues to be an important resource for the biotech investment community.”

Panelists from Biotech Showcase, Digital Health & Medtech Showcase, and China Showcase took the time to provide their expertise on several key issues facing the industry. This year’s speakers included leaders from Celgene, Novo Nordisk, Roche, NEA, Third Rock, Venrock, Raymond James, Pappas Capital, Blackrock, Piper Jaffray, and many more. Major sponsors of the conference included Syneos Health, AstraZeneca, Covington, Hogan Lovells, Johnson & Johnson Innovation, ClearView Healthcare Partners, and Lonza.

The next Biotech Showcase will be held January 13-15, 2020 in San Francisco. For more information go to BiotechShowcase.com.

Upcoming Events